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The Wellcome Trust Case Control Consortium 2 genome-wide association study reported an association between a 
genetic variant on chromosome 7p21.1 and an increased risk 
of ischemic stroke because of large artery disease.1 The asso-
ciation was confined to large artery stroke and not present with 
cardioembolic or lacunar stroke. The association has been rep-
licated in other cohorts of patients with stroke.2,3 The same 
genetic variant has also been associated with increased carotid 
intima–media thickness and asymptomatic carotid plaque,4 
and less strongly, with coronary artery disease,5 suggesting 
an action via increasing atherosclerosis. The underlying gene 
is thought to be histone deacetylase 9 (HDAC9 ).4 Mice with 
a deficiency of the HDAC9 gene (HDAC9−/− apolipoprotein 
E–deficient) exhibit reduced aortic atherosclerosis compared 
with HDAC9+/+ apolipoprotein E–deficient mice that do not 
have a deficiency.6 Furthermore, HDAC9 expression is upreg-
ulated in symptomatic carotid atherosclerotic plaques in man.4
The antiepileptic drug (AED) sodium valproate (SVA) is a 
nonspecific inhibitor of HDAC9 activity7 and has been shown 
to attenuate atherosclerosis in apolipoprotein E–deficient 
mice.8 A large Danish study suggested that although epilepsy 
was associated with an increased risk of incident stroke, the 
extent of this effect varied with the type of AED that was 
prescribed. SVA was associated with a decreased risk of 
both stroke and myocardial infarction compared with car-
bamazepine.9,10 A further large community study found a 
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dose–response relationship with higher doses of SVA being 
associated with lower risks of incident stroke, but similar 
associations were also seen with some other AEDs, raising the 
possibility of survivor bias.11
These findings raise the hypothesis that inhibiting HDAC9 
activity might offer a novel preventative treatment for large artery 
atherosclerotic ischemic stroke. We sought to indirectly test this 
hypothesis by exploring the association between exposure to 
SVA and subsequent risk of recurrent stroke in 3 large cohorts 
of patients with prior stroke or transient ischemic attack (TIA).
Methods
Data Sources
This project used data provided to us by 3 long-term follow-up stroke 
studies. Access to these separate data sources is therefore not avail-
able via this project.
Data were collected, and pooled, from 3 prospective studies 
recruiting patients with previous stroke or TIA and with long-term 
follow-up:
The SLSR (South London Stroke Register; n=4972) was a 
prospective population-based cohort study to record first-ever 
strokes in Lambeth and Southwark, London, United Kingdom.12 
The final data set included data collected for patients with first-
ever strokes between January 01, 1995, and September 30, 
2014. Stroke diagnosis was confirmed by a study physician 
within 1 week of the event. Face-to-face follow-up took place 
at 3 months and then annually after the index event. For patients 
reaching at least 1 follow-up, the mean time from initial stroke 
to final follow-up was 4.6 years (SD=4.4; range=0–19);
The VITATOPS (Vitamins to Prevent Stroke Study; n=8164) 
was a clinical trial recruiting patients based on any stroke or TIA 
within the 7 months preceding randomization.13 Randomization 
took place between January 17, 1997, and December 29, 2008. 
Follow-up took place every 6 months from randomization to 
trial completion, either face-to-face or by telephone. For pa-
tients reaching at least 1 follow-up, the mean time from ini-
tial stroke or TIA to final follow-up was 3.4 years (SD=2.4; 
range=0–11);
The OXVASC (Oxford Vascular study; n=2113) is a popula-
tion-based study of acute vascular events in Oxfordshire.14,15 
The data set included here comprised all recruits ascertained 
between April 03, 2002, and March 31, 2012, with any first 
ischemic stroke or TIA in the study period. Multiple methods of 
follow-up were used, including face-to-face follow-up. Follow-
up took place at 1, 6, 12, 24, 60, and 120 months. The mean 
time from initial stroke or TIA to final follow-up in this subset 
was 4.3 years (SD=3.4; range=0–12).
Ethics
SLSR was approved by the following ethics committees: St Thomas’ 
Hospital, King’s College Hospital, Wandsworth, Riverside, and 
National Hospital for Neurology and Neurosurgery and the Institute 
of Neurology.
VITATOPS received ethics approval in the United Kingdom from 
the Multicentre Research Ethics Committee for Scotland, in New 
Zealand from the Multi-region Ethics Committee, and from local 
research ethics committees applicable to each participating center. 
The Oxford Vascular Study was approved by the local research eth-
ics committee (OREC A: 05/Q1604/70).
Data Extracted
Study Populations
Study entry date was recorded as the date of index stroke or TIA. 
Classification of initial stroke pathology as ischemic or hemorrhagic 
was taken from the Oxfordshire Community Stroke Project (OSCP) 
or TOAST classifications (Trial of ORG 10172 in Acute Stroke 
Treatment) according to which classification had the least missing 
data per study. Where this was not available, the cases were catego-
rized as unclassified.
Study End Point-Stroke Recurrence
Recurrent stroke occurrence and TOAST classification of recurrent 
ischemic stroke were collected across all studies. Stroke recurrence 
was captured at follow-up and subsequently checked by study physi-
cians. These were then subtyped based on the TOAST classification.16 
Data were censored if, without recurrence, the patient died, reached 
their final follow-up, or the study ended.
For the SLSR, stroke recurrence was defined as a new neurologi-
cal deficit >24 hours after incident stroke and not considered to be 
because of edema, hemorrhagic transformation, or intercurrent ill-
ness. Recurrence within 21 days of the index stroke was only included 
if a different location was clearly indicated. For VITATOPS, recurrent 
stroke was defined as a new disturbance of focal neurological change 
lasting >24 hours or resulting in death and confirmed on imaging; 
all of the recorded recurrences were >24 hours from the index event. 
For OXVASC, recurrent stroke was recorded as any new neurological 
event lasting >24 hours or resulting in death and confirmed by a study 
physician who reviewed the surviving patients, the case records, and 
imaging.
Antiepileptic Treatment
Prescription data for antiepileptic medication were available for all 
3 studies. Prescription data were recorded at baseline and then each 
follow-up. For OXVASC, AED data were available at baseline and 
1-year follow-up. For the SLSR records of SVA, carbamazepine, 
phenobarbital, phenytoin, gabapentin, lamotrigine, levetiracetam, and 
occasional less frequently prescribed medications (other) were avail-
able. For VITATOPS records of SVA, carbamazepine, phenobarbital, 
and phenytoin were available. For OXVASC, records of SVA, car-
bamazepine, phenobarbital, phenytoin, gabapentin, and lamotrigine 
were available.
Other Variables
Other variables included in the analyses were study, age, sex, and 
diagnosis of epilepsy. Diagnoses of epilepsy were captured separately 
to antiepileptic medication. This was defined either as an existing 
diagnosis at baseline, made by a qualified physician, or a diagno-
sis recorded at follow-up. For VITATOPS, seizures were recorded 
as adverse events at each follow-up. These were classified as epilep-
tic seizures where they met the criteria for the International League 
Against Epilepsy, and no baseline data were available on this. For the 
SLSR, baseline diagnoses were taken from patient medical records, 
and subsequent diagnoses were collected via self-report at follow-
ups. For the OXVASC study, this included people with a history of 
>1 seizure in later childhood or adult life recorded at baseline by 
self-report.
Statistical Analysis
Figure 1 shows the selection of patients, exposure groups, and recur-
rent events. Patients were excluded from analyses if they had a hem-
orrhagic qualifying event or were lost to first follow-up.
The SVA exposure population was defined based on any prescrip-
tion of SVA before recurrent stroke or study end. This was calculated 
based on any SVA-recorded exposure in the period preceding the 
study outcome, death, or final follow-up. We used the date of the first 
follow-up where there was a prescription of SVA to calculate this. 
SVA prescribed after recurrence was not considered SVA exposure.
Our protocol specified analysis was as follows: The SVA exposure 
populations were compared with 2 minimally selective control popu-
lations to avoid bias. (1) all other patients; this included everyone 
other than those receiving SVA; and (2) all other AED prescriptions: 
defined as any record of AED prescription at any time from study 
entry to final follow-up, including those with dates after recurrence 
but excluding those with concurrent prescriptions of SVA. Because 
the cohorts we used were from non-AED studies, the precise start 
date for AED use was not available and recorded instead as the first 
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follow-up visit at which their use was recorded. For this reason, we 
initially included AED use at any time as our control population
It follows that our minimally selective criteria for the control pop-
ulations could result in the other AED population, including some 
patients for whom AED prescriptions might be given after recurrent 
stroke. We, therefore, performed further secondary analyses with 
more restrictive comparison populations. We first compared patients 
receiving SVA with patients receiving no AEDs only, defined as 
patients without any AED prescriptions recorded before the study 
end or recurrent stroke. Second, we compared patients receiving SVA 
with patients only receiving other AED before stroke or study end 
based on the date of follow-up that these prescriptions were recorded.
Survival time was calculated as the number of days from the date of 
the index event (stroke or TIA) to the date of recurrent stroke occur-
rence or censoring. Life tables were calculated to describe the cumu-
lative stroke-free survival for the exposure groups at 1, 5, 10, and 15 
years. Survival curves were estimated with Kaplan–Meier and groups 
compared using the log-rank test in SPSS version 22. Cox regression 
was carried to calculate adjusted risk of a recurrent stroke. SVA expo-
sure (SVA versus control), age, sex, history of epileptic symptoms, ini-
tial event type (TIA or stroke), and study were included in the model.
A secondary prespecified analysis was to determine whether any 
protective associations with SVA were confined to patients with 
large artery stroke, as might be expected from the genetic associa-
tion data. Therefore, we repeated analyses in patients with large 
artery stroke.
Post hoc Cox regression analyses were performed for each study 
population individually. Exposure to SVA was compared with all 
patients without SVA exposure. Covariates were as above.
Results
Descriptive Data
The study cohort and patients included in the analysis are 
shown in the flow chart and in Table 1. A total of 11 949 
patients were included in the pooled analyses, all of whom 
had a confirmed ischemic event at entry and follow-up avail-
able. The number in the SVA group was 168, and for those 
on other AEDs was 530. The total number of outcome events 
were 17 of 168 for patients prescribed SVA; 1470 of 11 781 
for patients never prescribed SVA; 105 of 530 for patients pre-
scribed other AEDs at any time; 1426 of 11 312 for patients 
not prescribed AEDs; and 44 of 469 for patients prescribed 
other AED when selected as prestroke/study end.
Survival Models
The cumulative stroke-free survival, based on yearly data, 
was greater for the SVA group than for patients not prescribed 
SVA. Data are shown in Table 2.
For the nonselective control populations, Kaplan–Meier 
estimates were calculated for exposure to SVA, no exposure 
to SVA, and exposure to AED medication at any time. Log-
rank tests showed that the difference between SVA exposure 
and no SVA exposure was not significant (χ2[1]=2.7; P=0.1) 
although there was a graphical trend indicating a difference 
in survival based on exposure at later time points; and the dif-
ference between SVA exposure and any other AED exposure 
was significant (χ2[1]=9.6; P=0.002). For the survival plots, 
see Figures 2 and 3.
For the selective control populations, Kaplan–Meier esti-
mates were calculated for exposure to SVA, no exposure to 
AED medication, and exposure to any other AED medication 
prestroke/study end. A log-rank test showed that the differ-
ence between SVA exposure and no AED exposure was not 
significant (χ2[1]=2.91; P=0.088) although there was a graphi-
cal trend indicating a difference in survival at later time points, 
and the difference between SVA exposure and other AED 
exposure was not significant (χ2[1]=0.01; P=0.937).
Hazard Models Adjusted for Covariates
Cox hazard models were calculated and adjusted for covari-
ates. For the nonselective control comparisons, 2 models 
were created to account for the overlap in the control groups. 
Exposure to SVA was associated with a reduced risk of stroke 
compared with all patients without SVA exposure (hazard 
ratio [HR]=0.50; 95% confidence interval [CI], 0.31–0.82; 
Wald test, P=0.006). Exposure to SVA was associated with 
a reduced risk of stroke compared with the group prescribed 
other AEDs at any time (HR=0.41; 95% CI, 0.25–0.71; Wald 
test, P=0.001). For the selective control comparison, a single 
model was created. Group status was significant (Wald=27.9; 
P<0.0001). SVA was associated with a reduced risk of 
stroke compared with no AED exposure (HR=0.48; 95% CI, 
0.35–0.67; Wald test, P<0.0001). Exposure to SVA was not 
Figure 1. Flow cart of cases 
included in analysis. *Where 
prescription is before recurrent 
stroke or study end only. AED 
indicates antiepileptic drug; 
OXVASC, Oxford Vascular Study; 
SLSR, South London Stroke 
Register; SVA, sodium valproate; 
and VITATOPS, Vitamins to Pre-
vent Stroke Study.
 by guest on A
pril 6, 2018
http://stroke.ahajournals.org/
D
ow
nloaded from
 
Brookes et al  Sodium Valproate, HDAC Inhibition, and Stroke Risk   57
Table 1. Pooled Background Data for OXVASC, VITATOPS, and SLSR
Variable
All Pooled Ischemic  
Cases in Analysis SVA Exposure No SVA Exposure
Other AED  
Exposure*
Background Variables n=11 949 n=168 n=11 781 n=530
Baseline age, mean (SD), y 66.0 (13.5) 65.4 (13.7) 66.0 (13.5) 64.1 (14.5%)
Sex, male: n (%) 7065 (59.1) 93 (55.4) 6972 (59.2) 293 (55.3)
Epilepsy symptoms, n (%) 367 (3.1) 70 (41.7) 297 (2.5) 151 (28.5)
Diabetes mellitus, n (%)
  Yes 2583 (21.6) 37 (22) 2546 (21.6) 139 (26.2)
  No 9234 (77.3) 128 (76.2) 9106 (77.3) 387 (73)
  Missing 132 (1.1) 3 (1.8) 129 (1.1) 4 (0.8)
Hx hypertension (treatment), n (%)
  Yes 6272 (52.5) 82 (48.8) 6190 (52.5) 236 (44.5)
  No 5437 (45.5) 77 (45.8) 5360 (45.5) 277 (52.3)
  Missing 240 (2) 9 (5.4) 231 (2) 17 (3.2)
Hx hyperlipidemia (treatment), n (%)
  Yes 3172 (26.5) 49 (29.2) 3123 (26.5) 136 (25.7)
  No 8272 (69.4) 107 (63.7) 8190 (69.5) 359 (67.7)
  Missing 480 (4) 12 (7.1) 468 (4) 35 (6.6)
Hx myocardial infarction, n (%)
  Yes 1081 (9) 25 (14.9) 1056 (9) 56 (10.6)
  No 10 695 (89.5) 140 (83.3) 10 555 (89.6) 467 (88.1)
  Missing 173 (1.4) 3 (1.8) 170 (1.4) 7 (1.3)
Hx smoking, n (%)
  Current 2849 (23.8) 33 (19.6) 2816 (23.9) 135 (25.5)
  Ex 3564 (29.8) 51 (30.4) 3513 (29.8) 143 (27)
  Never 5380 (45) 78 (46.4) 5302 (45) 237 (44.7)
  Missing 156 (1.4) 6 (3.6) 150 (1.3) 15 (2.8)
Index event
  Stroke/TIA, stroke: n (%) 10 100 (84.5) 154 (91.7) 9946 (84.4) 498 (94)
  TOAST, n (% total sample)
   Large artery 2847 (23.8) 17 (10.1) 2830 (24) 108 (20.4)
   Cardioembolic 1220 (10.2) 12 (7.1) 1208 (10.3) 76 (14.3)
   Small vessel 4081 (34.2) 53 (31.5) 4028 (34.2) 154 (29.1)
   Multiple 161 (1.3) 6 (3.6) 155 (1.3) 7 (1.3)
   Other 97 (0.8) 0 (0) 97 (0.8) 11 (2.1)
   Undetermined 2686 (22.5) 65 (39) 2622 (22.3) 92 (17.4)
   Classification unavailable 856 (7.2) 15 (8.9) 841(7.1) 82 (15.5)
Recurrent stroke
  TOAST, n (% total sample)
   Large artery 175 (1.4) 1 (0.6) 174 (1.5) 9 (1.7)
   Cardioembolic 259 (2.2) 1 (0.6) 258 (2.2) 19 (3.6)
   Small vessel 249 (2.1) 1 (0.6) 248 (2.1) 22 (4.2)
   Multiple 13 (0.1) 0 (0) 13 (0.1) 0 (0)
(Continued )
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associated with change in risk of stroke compared with other 
AED exposure group when selected as prestroke/study end 
(HR=1.2; 95% CI, 0.66–2.02; Wald test, P=0.62).
Large Artery Stroke Analyses
Subgroup analyses were performed to determine whether any 
associations were specific to large artery stroke. For those 
patients with large artery index events, 17 patients were in the 
exposed to SVA group, 2830 were in the never exposed to 
SVA, of which 108 were exposed to AED medication other 
than SVA. Survival data are given in Table 3.
Kaplan–Meier estimates were computed. Although survival 
curves diverged for the groups, with a trend to better outcomes 
for those exposed to SVA, the data were limited by the small 
sample sizes. For a comparison between the SVA-exposed 
group and all other non-SVA–exposed patients, a log-rank 
test showed that the difference between the 2 survival curves 
was not significant (χ2[1]=0.073; P=0.787). For a comparison 
between the SVA-exposed group and the other AED group, a 
log-rank test showed that the difference between the 2 survival 
curves was not significant (χ2[1]=1.16; P=0.281).
Post Hoc Analyses
Cox hazard models were calculated per study. Exposure 
to SVA was associated with a trend toward a reduced risk 
of stroke compared with all patients without SVA exposure 
Table 2. Cumulative Survival for All Entry Events (% Stroke Free)
Confirmed Ischemic Stroke (n=13 021) With Follow-Up Data (n=11 949)
SVA Exposure*
No SVA
 Exposure† Other AED Exposure (All)‡ No AED Exposure
Other AED Exposure (Date 
Dependant)
n§ % n§ % n§ % n§ % n§ %
Year 1 168 97 11 781 94 530 92 11 312 94 469 98
Year 5 99 89 4878 85 231 79 4654 85 224 91
Year 10 17 86 784 79 70 72 715 78 69 84
Year 15 3 86 96 74 13 60 83 75 13 75
% Cumulative percentage stroke free based on yearly statistics. AED indicates antiepileptic drug; and SVA, sodium valproate.
*Where prescription is confirmed before recurrent stroke only.
†Includes patients exposed to other AEDs and patients never exposed to any AEDs.
‡All participants with other AED prescription recorded; no combined treatment with SVA.
§n entering analysis at beginning of time period.
   Other 9 (0.1) 0 (0) 9 (0.1) 0 (0)
   Undetermined 639 (5.3) 14 (8.4) 625 (5.4) 41 (7.7)
   Hemorrhagic 143 (1.2) 0 (0) 143 (1.2) 14 (2.6)
SVA exposure
  SVA exposure (recorded  
before recurrent stroke/study  
end only), n (%)
168 (1.4)    
Other AED exposure*
  Carbamazepine exposure, n (%) 161 (1.3) 11 (6.5) 150 (1.3) 150 (1.3)
  Phenobarbital exposure, n (%) 25 (0.2) 3 (1.8) 22 (0.2) 22 (0.2)
  Phenytoin exposure, n (%) 211 (1.8) 19 (11.3) 192 (1.6) 192 (1.6)
  Gabapentin exposure, n (%) 156 (1.3) 4 (2.4) 152 (1.3) 152 (1.3)
  Lamotrigine exposure, n (%) 12 (0.1) 2 (1.2) 10 (0.1) 10 (0.1)
  Levetiracetam exposure, n (%) 35 (0.3) 6 (3.6) 29 (0.2) 29 (0.2)
  Other AED exposure, n (%) 43 (0.4) 3 (1.8) 40 (0.3) 40 (0.3)
AED indicates antiepileptic drug; OXVASC, Oxford Vascular Study; SLSR, South London Stroke Register; SVA, sodium valproate; 
TOAST, Trial of ORG 10172 in Acute Stroke Treatment; and VITATOPS, Vitamins to Prevent Stroke Study.
*All participants with other AED prescription recorded; no combined treatment with SVA. Hypertension and hyperlipidemia based 
on premorbid treatment.
Table 1. Continued
Variable
All Pooled Ischemic  
Cases in Analysis SVA Exposure No SVA Exposure
Other AED  
Exposure*
n=11 949 n=168 n=11 781 n=530
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for VITATOPS (HR=0.52; 95% CI, 0.26–1.0; Wald test, 
P=0.052) and the SLSR (HR=0.33; 95% CI, 0.12–0.92; Wald 
test, P=0.033) but not OXVASC (HR=1.2; 95% CI, 0.40–3.4; 
Wald test, P=0.781).
Discussion
This analysis of 3 large cohorts of patients with prior stroke or 
TIA was undertaken to explore an a priori hypothesis (ie, the 
hypothesis was generated from published studies1–11 before 
the epidemiological data were analyzed) that exposure to an 
inhibitor of HDAC, in the form of SVA, may be associated 
with a lower risk of recurrent stroke compared with nonex-
posure or to exposure to other AEDs. Although the design 
of our study is prone to systematic and random error and 
cannot infer causality, the results provide some evidence for 
the prestudy hypothesis and suggest that SVA, a nonspecific 
HDAC inhibitor, may be associated with a reduced stroke 
recurrence rate.
Previously, data have suggested that SVA reduces stroke risk 
in a stroke-free population, but this analysis provides new data 
suggesting that such an effect can also be found in patients 
who have already presented with ischemic stroke. This is 
Figure 2. Survival curve comparing propor-
tion of population free of recurrent stroke, 
in patients on sodium valproate (SVA) com-
pared with those not on SVA.
Figure 3. Survival curve comparing propor-
tion of population free of recurrent stroke, 
in patients on sodium valproate (SVA) com-
pared with those on other antiepileptic drug 
(AED).
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particularly relevant if HDAC9 inhibition is to be considered as 
a potential secondary preventative treatment for stroke.
The results are broadly consistent with the results of 2 
large population-based studies in Denmark and the United 
Kingdom. In a Danish study, SVA was associated with a lower 
risk of both myocardial infarction and stroke when com-
pared with other AEDs.9,10 In the British study, which used 
the Clinical Practice Research Database, SVA exposure was 
associated with a reduced risk of myocardial infarction but not 
ischemic stroke.11 However, when a dose–response analysis 
was performed, longer exposure to SVA was associated with 
a reduced risk of ischemic stroke although similar associa-
tions were found with other AEDs raising questions about the 
specificity of the association.
In our study when comparing SVA use with all other 
patients with ischemic stroke and those patients with ischemic 
stroke on no AED, there was a highly significant reduced risk 
of stroke. This was replicated in our preplanned analysis com-
paring patients with SVA with those taking any other AED. 
Because of the use of cohorts collected for other study pur-
poses, we did not have a precise start date for AEDs, and we 
therefore used the date of the follow-up at which the medica-
tion was recorded. For this reason, we initially included AED 
use at any time as our control population. However, when we 
performed further exploratory analyses in the data where the 
AED record dates were before recurrent stroke, the difference 
was no longer significant. This raises the possibility that the 
significant risk reduction seen in the SVA group compared 
with the 3 control groups might be because of some differ-
ence if patient characteristics between the 2 groups. Such bias 
are impossible to exclude in a cohort study, such as this, and 
confirming whether SVA does indeed reduce stroke risk will 
require a randomized trial design. One potential bias might be 
if stroke subtype differs in patients on SVA, for example, lacu-
nar stroke might have a lower risk of epilepsy requiring AED 
therapy and a lower risk of stroke recurrence. However, there 
was no evidence of any difference in lacunar stroke frequency 
between groups (Table 1). A second possible issue is related 
to the collection of prescription dates which were based on 
follow-up rather than prescription date. Alternatively, it may 
be a possibility that other AEDs also have some inhibitory 
effect on HDAC9 although evidence for this is less clear. 
Notwithstanding, SVA exposure appeared overall to have a 
positive effect compared with no SVA exposure.
Strengths of this study include the prospective design, stan-
dardized diagnostic criteria for the qualifying TIA and stroke, 
and prolonged follow-up. Two of the 3 cohorts were popula-
tion-based studies, reducing the risk of any selection bias. The 
third was a large randomized clinical trial that again incorpo-
rated prolonged follow-up.
However, the data sets also had some limitations. When 
examined separately as a post hoc analysis, 2 of the data sets 
yielded the same trend toward and effect for SVA, OXVASC 
did not. However, OXVASC had a small number of patients 
with confirmed SVA exposure (n=11), making it difficult to 
interpret in isolation. Sufficient data were not available to 
assess dose–response relationships, and therefore analyses 
were restricted to SVA prescribed at any time during follow-
up. Because of the nature of data collection, often at annual 
follow-up, determining the exact start date of AED was not 
possible, and these were recorded as starting at the time the 
patient was first followed-up on that AED. Despite the large 
sample size of the >10 000 patients with stroke, the number of 
participants taking SVA and other AEDs was relatively few (in 
the hundreds) which limited statistical power. Furthermore, 
the number of cases of large artery stroke was too small to 
reliably test whether any protective effect was specific to this 
subtype, as hypothesized from the genetic association data.1 It 
is also inherent in this type of data that the outcomes are more 
heavily weighted in the early years (because of early recur-
rence and long follow-up), but this is consistently the case 
across comparison groups. It may be that data sets with more 
power would benefit for an analysis splitting short- and long-
term outcomes in relation to AED medication.
It is also acknowledged that SVA is a nonspecific HDAC 
inhibitor (inhibiting a wide range of HDACs) and has other 
actions, independent of HDAC9 inhibition. Hence, a more 
specific inhibitor of HDAC9 might have a stronger effect in 
reducing the risk of recurrent stroke. HDACs are a class of 
enzymes that remove acetyl groups from an ε-N-acetyl lysine 
amino acid on a histone, allowing the histones to wrap the 
DNA more tightly. There are 18 HDACs in humans. Eleven 
of the HDACs are zinc dependent, classified on the basis of 
homology to yeast HDACs: class I includes HDACs 1, 2, 3, 
and 8; class IIA includes HDACs 4, 5, 7, and 9; class IIB, 
HDACs 6 and 10; and class IV, HDAC11.17
This study provides some support for the hypothesis that 
HDAC9 is important in the pathogenesis of ischemic stroke 
and that its inhibition, by SVA or a more specific HDAC9 
inhibitor, is worthy of evaluation as a treatment to prevent 
recurrent ischemic stroke. However, because of limitations in 
a cohort study of this design, and possible unidentified bias, 
determining whether HDAC9 inhibition does reduce stroke 
risk requires randomized controlled trials of SVA or other 
HDA9 inhibitors.
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